Complete remission of a hypereosinophilic syndrome by imatinib;Komplette remission eines idiopathischen hypereosinophilen syndroms unter imatinib

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 40, 2004, Pages 2104-2106

  Wolf, Dominik ^a   Gastl, C ^a   Rumpold, H ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; ENZYME INHIBITOR; FIP1L1 PDGFRA FUSION PROTEIN, HUMAN; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; AMNESIA; ARTICLE; ATAXIA; BLOOD; CASE REPORT; CHROMOSOME 4Q; CHROMOSOME DELETION; DYSARTHRIA; FIP1L1 GENE; FUSION GENE; GENE LOCUS; GRANULOMATOUS VASCULITIS; HEMATOLOGIC MALIGNANCY; HUMAN; HYPEREOSINOPHILIC SYNDROME; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PDGFRA GENE; REMISSION; BRAIN VASCULITIS; DRUG ANTAGONISM; DRUG EFFECT; EOSINOPHIL; GENETICS; MIDDLE AGED;

ENZYME INHIBITORS; EOSINOPHILS; HUMANS; HYPEREOSINOPHILIC SYNDROME; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REMISSION INDUCTION; VASCULITIS, CENTRAL NERVOUS SYSTEM;

EID: 6044233298     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-831852     Document Type: Article

References (10)

1. Bain B, Imbert M, Vardiman JW, Bruning RD, Flandrin G. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. Lyon, France: IACR Press, In: Jaffe, ES., Harris, NL, Stein, H., Vardiman, JW. eds. World Health Organization of Tumours: Tumours of Haematopoetic and Lymphoid Tissue. 2001: 29-31
2. Bain B. The idiopathic hypereosinophilic syndrome and eosinophilic leukemias. Haematologica 2004; 89: 133-137
3. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J et al. Tyrosine kinase created by fusion of the PDGFRA and FlP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic Syndrome. N Engl J Med 2003; 348: 1201-1214
4. Cools J, Quentmeier H, Huntly BJ, Marynen P, Griffin JD, Drexler HG, Gilliland DG. The EOL-1 cell line as an in vitro model for the study of FlP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2004; 103:2802-2805
5. Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003; 102: 83-86
6. Goldman J, Apperley J, Kanfer E, Olavarria E, Marin D. Imatinib or transplant for chronic myeloid leukaemia? Lancet 2003; 362: 172-173
7. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873-2878
8. Klion AD, Robyn J, Akin, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103: 473-478
9. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004; 11: 35-43
10. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: Role of the platelet-derived growth factor receptor beta. Acta Haematol 2002; 107: 113-122